Brenig Therapeutics
- Company typePrivate
- Founded2021
- HeadquartersDover, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Brenig Therapeutics firmographics
Firmographics- Name
- Brenig Therapeutics
- Legal name
- Brenig Therapeutics, Inc.
- Website
- https://brenigther.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Brenig Therapeutics industry classification
Industry- Product category
- Biopharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
- akta.pro secondary industries
- Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA), Cheminformatics & Molecular Modeling / CADD (HLAGAJAE), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)
Keywords
Where Brenig Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Dover
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Brenig Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- Pharmaceutical Licensing and Development Deals: As a pre-revenue clinical-stage biotech, Brenig's primary revenue model will likely involve licensing its drug candidates to pharmaceutical partners, receiving milestone payments tied to development and regulatory milestones, and ultimately royalty payments from product sales. The company is advancing BT-267 and BT-409 through clinical development toward commercialization.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Brenig Therapeutics product offering
Product offeringCore offering
Brenig Therapeutics is a clinical-stage biotechnology company developing brain-penetrant small-molecule drug candidates for neurodegenerative diseases, with a primary focus on Parkinson's disease. Its lead asset BT-267 is a selective LRRK2 inhibitor, and BT-409 is a brain-penetrant NLRP3 inflammasome inhibitor, both designed through Brenig's proprietary Hybrid AI Drug Discovery Platform built in partnership with Expert Systems Inc. The company currently has two candidates in Phase 1 clinical trials and intends to commercialize through pharmaceutical partnerships upon regulatory approval.
Product overview
Brenig Therapeutics is a clinical-stage biotechnology company pioneering small-molecule therapies for neurodegenerative diseases. The company's core portfolio consists of two clinical-stage drug candidates: BT-267, a LRRK2 inhibitor for Parkinson's disease currently in Phase 1 trials, and BT-409, a brain-penetrant NLRP3 inhibitor for neuroinflammatory diseases also in Phase 1 development. Both programs were developed using Brenig's proprietary Hybrid AI Drug Discovery Platform, which combines physics-based structural biology with machine learning to accelerate the design and optimization of brain-penetrant small molecules.
Differentiator
Problem solved
Functional benefit
Products and services
- BT-267 Selective, brain-penetrant small-molecule inhibitor of leucine-rich repeat kinase 2 (LRRK2) in Phase 1 clinical development as a potential best-in-class, disease-modifying treatment for Parkinson's disease. Designed to maximize CNS exposure while minimizing peripheral activity, with demonstrated high kinome selectivity (1000x), exceptional CSF/unbound plasma ratio in non-human primates, and no visible lung or kidney morphological changes at the highest tested doses in GLP toxicology studies.
- BT-409 Highly selective, CNS-penetrant small-molecule inhibitor of the NLRP3 inflammasome in Phase 1 clinical development as a potential best-in-class therapy for Parkinson's disease and other neurodegenerative and neuroinflammatory disorders. Engineered to deliver brain-specific NLRP3 inhibition while minimizing on- and off-target effects. Licensed by Brenig from Mwyngil Therapeutics in 2025.
Quantifiable outcome
- BT-267 demonstrates 1000x selectivity against other kinases and >500x selectivity against other targets from safety panel
- +3 more outcomes
Companies that use Brenig Therapeutics
Customer profileSegments2 records
Ideal customer profiles2 records
Brenig Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature4 records
Brenig Therapeutics partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and flagship.
- ChemDiv, Inc.coreGlobal provider of integrated drug discovery solutions. Supports Brenig's CNS drug discovery programs through proprietary CNS-focused drug discovery platform. Has enabled design and optimization of brain-penetrant small-molecule programs.
- Expert Systems Inc.flagshipStrategic partnership for development of Hybrid AI drug discovery platform. Integrates Expert Systems' proprietary AI-driven drug discovery technologies with Brenig's therapeutic focus. Platform enables concurrent co-optimization of drug properties including potency, selectivity, safety, and CNS exposure.
- Mwyngil TherapeuticscoreLicensed BT-409 (brain-permeable NLRP3 inhibitor) from Mwyngil Therapeutics in 2025. BT-409 was originally discovered by Mwyngil using its AI and machine learning drug accelerator platform. Brenig acquired and is advancing the program through clinical development.
Scale indicators2 records
Recent moves6 records
Expansion highlights5 records
Brenig Therapeutics competitors and assessment
Company assessmentEmerging players
- Yumanity Therapeutics: Clinical-stage biotech developing disease-modifying therapies for Parkinson's and ALS; comparable as a small-cap neuroscience biotech focused on neurodegenerative diseases.
- Mwyngil Therapeutics: Developer of BT-409 (NLRP3 inhibitor) before licensing it to Brenig; comparable as a small AI/ML-enabled CNS biotech and direct licensor/partner of Brenig's second clinical asset.
- BioAge Labs: Clinical-stage biotech using AI/ML for drug discovery targeting aging-related diseases including neurodegeneration; comparable as an AI-driven CNS drug discovery peer at similar stage.
Broad incumbents
- Prevail Therapeutics: Gene therapy-focused biotech (acquired by Lilly) developing AAV-based therapies for Parkinson's and other neurodegenerative diseases; comparable in neurodegenerative disease focus, though uses a different modality.
- Cerevel Therapeutics: CNS-focused biotech (acquired by AbbVie in 2024) developing therapies for Parkinson's and other neurological disorders; comparable in therapeutic focus and pipeline-stage CNS specialization.
- Sage Therapeutics: Specialty CNS pharmaceutical company with approved CNS therapies and pipeline in neurological/psychiatric indications; comparable as a CNS-focused biotech that achieved commercialization in CNS specialty.
Direct peers
- Annovis Bio: Clinical-stage biotech developing small-molecule therapies for Parkinson's and other neurodegenerative diseases; comparable in indication focus (Parkinson's) and small-cap clinical-stage status.
- Neumora Therapeutics: Clinical-stage CNS-focused biotech pursuing precision medicines for brain diseases including Parkinson's; Brenig's CMO Tien Dam was previously VP Clinical Development at Neumora, making it an institutional and therapeutic-area peer.
- Prothena Corporation: Clinical-stage biotech developing therapies for neurodegenerative diseases including Parkinson's; comparable in indication focus and pipeline-stage development of CNS-targeted therapeutics.
- Denali Therapeutics: Clinical-stage biotech developing LRRK2 inhibitors for Parkinson's disease — the most direct head-to-head competitor to BT-267 in the LRRK2 pathway with significantly more advanced clinical assets and larger capitalization.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
Brenig Therapeutics social profiles
Digital presenceBrenig Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Brenig Therapeutics leadership team
Management profileNumber of profiles
Profiles8 records
Brenig Therapeutics funding detail
Funding detailFunding overview
Funding rounds1 record
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Brenig Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Brenig Therapeutics
What does Brenig Therapeutics do?
Brenig Therapeutics is a clinical-stage biotechnology company developing brain-penetrant small-molecule drug candidates for neurodegenerative diseases, with a primary focus on Parkinson's disease. Its lead asset BT-267 is a selective LRRK2 inhibitor, and BT-409 is a brain-penetrant NLRP3 inflammasome inhibitor, both designed through Brenig's proprietary Hybrid AI Drug Discovery Platform built in partnership with Expert Systems Inc. The company currently has two candidates in Phase 1 clinical trials and intends to commercialize through pharmaceutical partnerships upon regulatory approval.
Is Brenig Therapeutics a public or private company?
Brenig Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Brenig Therapeutics founded?
Brenig Therapeutics was founded in 2021. It employs 11 to 50 people.
Where is Brenig Therapeutics based?
Brenig Therapeutics is headquartered in Dover, United States, in the North America region.
How does Brenig Therapeutics make money?
One revenue line is on record: pharmaceutical Licensing and Development Deals.
Who are Brenig Therapeutics's main competitors?
Emerging players on record are Yumanity Therapeutics, Mwyngil Therapeutics and BioAge Labs. Broad incumbents are Prevail Therapeutics, Cerevel Therapeutics and Sage Therapeutics. Direct peers are Annovis Bio, Neumora Therapeutics, Prothena Corporation and Denali Therapeutics.
Does Brenig Therapeutics have an API?
No public API is recorded for Brenig Therapeutics.
What industry is Brenig Therapeutics in?
Brenig Therapeutics's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery). Its NAICS code is 541714 and its SIC code is 2834.